Phase 1
Completed N=8
A Study of LY3314814 in Healthy Participants
Healthy
Source: ClinicalTrials.gov NCT03222427 ↗
Enrolled (actual)
8
Serious AEs
0.0%
Results posted
Mar 2019
Primary outcomePrimary: Absolute Bioavailability of LY3314814 — 60.5; 59.2 nanogram*hour per milliliter per mg
Summary
The purpose of this study is to measure how much LY3314814 gets into the bloodstream when it is given as a single dose by mouth and as an intravenous (IV) infusion over two hours. The study will last at least two weeks for each participant, not including screening.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Absolute Bioavailability of LY3314814 |
60.5; 59.2 | — |
| SECONDARY Pharmacokinetics: Area Under the Drug Concentration-Time Curve From Zero to Infinity (AUC[0 ∞]) of LY3314814 and [13C415N3] LY3314814 |
3020; 5.92 | — |
Eligibility Criteria
Inclusion Criteria
- Are overtly healthy males or females
- Have venous access sufficient to allow for blood sampling and intravenous (IV) administration of the investigational product
Exclusion Criteria
- Have a history of significant ophthalmic disease
- Have vitiligo or any other clinically significant disorder of skin pigmentation
- Have a history of use of antipsychotic drugs, or chronic use of antidepressant or anxiolytic drugs, prescribed as well as non-prescribed
Data sourced from ClinicalTrials.gov (NCT03222427). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.